Plastomics, Inc.
St. Louis, US · Founded 2017 · Delaware corporation · 22 employees on LinkedIn · 8 known investors
Find your way into Plastomics, Inc.
134 people in our graph share verified history with the Plastomics, Inc. team — schools, employers, funds. One of them is your warm intro.
Ann Miura-Kounlockedknows Jeffrey Staub · together at Yale University (overlapped)
×4knows the team · via Monsanto Company
knows the team · via Impetus Agriculture, Inc.
knows the team · via Solis Agrosciences
knows the team · via Yale University
×4knows the team · via University of Maryland Baltimore County
Plastomics develops trait delivery technology for agriculture using cell biology, plant tissue culture, transformation, and molecular biology methods. The company serves the agricultural industry with next-generation biotechnology solutions.
Founders & leadership
JS
Jeffrey StaubinChief Product OfficerJeffrey Staub founded Plastomics in 2016 and serves as Executive Officer and Director. He has 19+ years of experience in biotechnology at Monsanto and holds expertise in plant transformation, organelle genetics, and molecular biology, including co-invention of plant plastid transformation technology.
EG
Elizabeth GallegosinFounder, CFO/COO2017–2022
Board
MS
BC
CB
Charles BoltenBoard director
DD
Dave DuncanBoard director
Investors · 8
BioGenerator VenturesSt. Louis · $50K – $250K
Fulcrum Global CapitalKansas Cityvia John Peryam · board
iSelect FundSt. Louis · $250K – $2M
Missouri Technology CorporationSt. Louis
Cultivation CapitalreportedSt. Louis · $100K – $3.5M
Prolog VenturesreportedClayton · $250K – $1Mvia Brian Clevinger · board
Also in the syndicate · 2
Lewis & Clark PartnersSkull Diamond and Heart Capital
Funding
SEC filings, press & company announcements$18.5M disclosed across 4 of 5 rounds · 2017–2025
- $5.8MSeries BOct 2025 · 4 sources
BioGenerator Ventures, Fulcrum Global Capital, Lewis & Clark Partners, Missouri Technology Corporation, Skull Diamond and Heart Capital
Source ↗
▶$7.1MraisedDec 2021 · 13 investors · AgricultureRule 506(b)
▶$7.1MraisedDec 2021 · 13 investors · Agriculture
Rule 506(b)Officers, directors & promoters on the filing
- Steve WelkerDirector
- Brian ClevingerDirector
- Charles BoltenDirector
- Gallegos ElizabethExecutive Officer
- Jeffrey StaubExecutive Officer, Director
- Martha SchlicherExecutive Officer, Director
- John PeryamDirector
- Offering amount
- $7.1M
- Amount sold
- $7.1M
- Minimum investment
- $50K
- Proceeds to insiders
- $700K
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$3.2MraisedMay 2021 · 17 investors · AgricultureRule 506(b)
▶$3.2MraisedMay 2021 · 17 investors · Agriculture
Rule 506(b)Officers, directors & promoters on the filing
- Charles BoltenDirector
- Martha SchlicherExecutive Officer, Director
- Dave DuncanDirector
- Elizabeth GallegosExecutive Officer
- Jeffrey StaubExecutive Officer, Director
- Brian ClevingerDirector
- Offering amount
- $3.3M
- Amount sold
- $3.2M
- Minimum investment
- $25K
- Proceeds to insiders
- $90K
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2.4MraisedMar 2021 · 11 investors · AgricultureRule 506(b)
▶$2.4MraisedMar 2021 · 11 investors · Agriculture
Rule 506(b)Officers, directors & promoters on the filing
- Martha SchlicherExecutive Officer, Director
- Charles BoltenDirector
- Brian ClevingerDirector
- Dave DuncanDirector
- Elizabeth GallegosExecutive Officer
- Jeffrey StaubExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $2.4M
- Minimum investment
- $15K
- Proceeds to insiders
- $400K
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Plastomics, Inc. went on to found or lead other companies.
Competitors · 8
by search overlapTagomics6 shared keywordsTagomics develops multimodal technologies for precision medicine and next-generation diagnostics. The company is based in Cambridge and focuses on improving patient outcomes through advanced diagnostic technologies.
Genomics Plc5 shared keywordsGenomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers. It serves life sciences companies and healthcare systems through its Life Sciences and Health & Wellness divisions.
Verinomics5 shared keywordsVerinomics develops crop improvement technology by combining genomics, computational biology, and a transgene-free gene editing platform, with an AI-driven population genomics tool to identify high-value trait genes. It serves breeding programs, agricultural businesses, and research institutions focused on specialty and vegetatively propagated crops such as leafy greens.
Buynomics4 shared keywordsBuynomics builds a Virtual Shoppers AI that integrates multiple data sources to predict shopper behavior and support commercial and pricing decisions for enterprises. It serves Revenue Growth Management and commercial teams primarily in the CPG, telecommunications, retail, and software industries.
Phenomic AI4 shared keywordsPhenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.
Phinomics4 shared keywordsPhinomics is a cancer drug discovery platform that captures extrachromosomal circular DNA (the "Circulome") at high resolution from matched tumor and normal patient samples, integrating it with DNA, RNA, epigenetics, and proteomics into a multi-omic knowledge graph. It applies explainable AI to this data to identify novel therapeutic targets, resistance mechanisms, and patient stratification biomarkers for oncology therapeutics development.
Bioloomics3 shared keywordsBoulder-based preclinical biotech using human-cell directed evolution to create target-degrading antibodies and next-generation ADCs.
Canomiks3 shared keywordsCanomiks is a life sciences company focused on developing treatments and research in diabetes, cardiovascular disease, and related areas, drawing on expertise in pharmacology, genomics, and bioinformatics.
Companies competing with Plastomics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2020 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Plastomics, Inc. do?
- Plastomics develops trait delivery technology for agriculture using cell biology, plant tissue culture, transformation, and molecular biology methods. The company serves the agricultural industry with next-generation biotechnology solutions.
- Who are Plastomics, Inc.'s investors?
- Plastomics, Inc.'s investors include BioGenerator Ventures, Fulcrum Global Capital, iSelect Fund, Missouri Technology Corporation, Cultivation Capital, Prolog Ventures.
- How much funding has Plastomics, Inc. raised?
- Plastomics, Inc. has disclosed $18.5M raised across 4 of its 5 known rounds.
- Where is Plastomics, Inc. headquartered?
- Plastomics, Inc. is headquartered in St. Louis, US.